30 July 2026
30 July 2026
Researchers estimate that pharma could unlock up to $1.2tn in commercial value from tropical forests by supporting biodiversity conservation.
Capricor is adamant its Phase III study showed effectiveness, though panel members called data “fragile”.
GSK will reallocate a large portion of capital saved from the £1.9bn cost-cutting scheme towards late-stage pipeline acceleration, primarily focused on oncology.
If approved, uniQure’s AMT-130 would be the first disease-modifying treatment for the inherited neurodegenerative disorder.
Regenerative medicine offers an innovative approach to treating different indications by restoring damaged or diseased cells and tissues.
The recommendation is based on data from the Phase III VESALIUS-CV trial, which involved more than 12,000 patients.
Dimerix adds DMX-652, a Phase II-ready AKI asset, strengthening its kidney disease pipeline beyond FSGS.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
